This article discussed the current multimodality approach to the management of rectal cancer and provides a thorough review of each discipline. Today, stage II to III mid to low rectal cancers in the United States receive neoadjuvant chemoradiation (50.4 Gy and continuous infusion 5-FU over 5 to 6 weeks) followed by surgical resection with TME in 6 to 8 weeks. The authors emphasize that the greatest effects of this approach has been a decrease in local recurrence and an increase in sphincter preservation rate. Newer radiotherapeutic, chemotherapeutic, and surgical techniques were included in this review to demonstrate methods of effectively decreasing the morbidity associated with this approach. The discussion is evidence-based and highlights significant contributions to this field within the literature.
Gearhart SL. Induction Chemoradiation for Rectal Cancer—Invited Critique. Arch Surg. 2006;141(12):1253. doi:10.1001/archsurg.141.12.1253